Search
Displaying 451–460 of 714 for “retinitis clinical trial”
-
Foundation’s No-Cost Program Increased Genetic Testing Rates for IRD Patients
Research NewsMore than 8,000 people have applied for genetic testing through the Foundation’s program
-
In the Press
Round was led by Sofinnova Investments with participation from Abingworth, Lightstone Ventures and all existing investors.
Company expands board of directors and plans to build out team.
-
Foundation Fighting Blindness Commits $6.5 Million for New Retinal Disease Research Grants
Foundation NewsNew grants include development of CRISPR/Cas9 gene-editing treatments, new disease models, and a retinal regeneration therapy
-
Information for Newly Diagnosed Patients and their Loved Ones
-
Foundation News
Three-day conference in San Diego will feature retinal science’s leading researchers and clinicians, and focus on the year’s top science and emerging treatments
-
Foundation News
The primary goal of the landmark study, funded by the Foundation, is to provide companies and researchers with disease-progression data and potential clinical trial endpoints to drive therapy development
-
The FDA's Indispensible Role (a guest blog from Dr. Patricia Zilliox)
Research NewsWhile it may not seem obvious, the FDA ultimately drives everything — the researchers and the money. That’s because without FDA approval, you have no treatment, even if you have great research and adequate funding.
-
Celebrating Genetic Counselor Awareness Day with Kristy Lee
Beacon StoriesOn Genetic Counselor Awareness Day, we celebrate the invaluable contributions of genetic counselors, whose dedication guides individuals through the complexities of genetic information, offering support, and fostering hope. We’re highlighting Kristy Lee, MS, CGC, whose work brings clarity for countless patients and families navigating genetic diseases.
-
To make a bigger impact on our mission to turn early research into clinical trials for people with IRDs and dry AMD, the Foundation will grow its network of collaborators and partners.
